Loading page
Strong idea · still checking
Mineralys Therapeutics, Inc.
Expected time 1 year is when we expect the main question to be answered. Full holding time 9-15 months is the longest the idea may stay open if the facts still support it.
Reviewed Sep 2, 2026
Long MLYS for a 1-year regulatory-to-commercial rerating around lorundrostat.
Long MLYS for a 1-year regulatory-to-commercial rerating around lorundrostat. The market is still assigning heavy single-asset biotech risk, but the NDA has been accepted with a December 22, 2026 PDUFA, pivotal trials showed clinically meaningful blood-pressure reductions, and the company reported $661.4 million of cash, equivalents and investments with funding into 2028 including launch. AstraZeneca's approved BAXFENDY creates real commercial pressure, but it also validates aldosterone synthase inhibition as a new hypertension category. Approval with a usable label can shift Mineralys from binary development risk toward launch execution value.
Expected holding period: 9-15 months
These are TickerYou's own possible outcomes—not Wall Street targets or copied internet forecasts. Lower is what may happen if important facts disappoint, middle is our main working case, and higher is what may happen if things go better than expected. These are checks for the research, not promises.
We will check this set through 6-12 months. The expected holding period (9-15 months) is the broader time we may follow the Idea, so the two dates do not need to match. We show longer-term estimates only when the supporting business and price assumptions are written down.
Where these numbers came from. Published Aug 24, 2026 against $25.45 using a saved Yahoo Finance price as of Aug 24, 2026.
| Time frame | Check by | Lower case | Middle case | Higher case | Source strength | What happened |
|---|
Loading company facts
Loading reported-quarter evidence
Checked through Sep 2, 2026
Each source says whether it supports the idea, challenges it, or adds background. A quick no-change check may update the review date without replacing these sources.
Mineralys reported that FDA continued reviewing lorundrostat with a 2026-12-22 PDUFA date, commercial preparations were on track, cash and investments were $661.4 million at 2026-06-30, and funding was expected into 2028 including launch.
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (ir.mineralystx.com)Mineralys reported positive topline Launch-HTN and Advance-HTN pivotal results, including statistically significant placebo-adjusted systolic blood-pressure reductions and disclosed hyperkalemia rates above 6.0 mmol/L in both trials.
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant HypertensionWe rated 3 of 3 upcoming events. 1 is both likely and important.
51 of 100 = chance 0.85 × effect 0.6 × date nearness 0.99.
66 of 100 = chance 0.85 × effect 1 × date nearness 0.78.
Checks are shown newest first. Repeated copies are folded together on screen, while every saved record remains unchanged.
Previously we believed MLYS could rerate from accepted-NDA risk toward launch value if lorundrostat reached approval with a usable hypertension label. Searches found no cutoff-eligible dated development after 2026-08-30; reopened primary sources confirm the December 22, 2026 PDUFA, cash runway and pivotal efficacy baseline, while AstraZeneca's approved Baxfendy remains the main competitive challenge.
We previously believed MLYS could rerate if lorundrostat's NDA stayed on track for a 2026-12-22 PDUFA and an approval came with a commercially usable label, despite AstraZeneca's first-mover competition. Searches found no material dated development after 2026-08-28; reopened primary sources still show FDA review continuing, launch preparations on track, cash and investments of $661.4 million with runway into 2028, and Baxfendy already approved in the same mechanism class. The invalidation trigger has not fired because the PDUFA date remains future and no sourced nonapproval or restrictive label has appeared.
1 check left
Reopened 2026-08-11, 2025-03-10 and 2026-05-18 primary sources confirm PDUFA timing, launch preparation, cash runway, pivotal blood-pressure data, and Baxfendy competition.
FDA approval, final label language, monitoring requirements, payer access, and uptake versus Baxfendy remain unresolved.
No ready estimate is issued while checks are missing. The $40.00 research scenario remains below for context, without possible-move or sizing language.
FDA could reject lorundrostat, request additional data, or approve with monitoring or population limits that prevent a broad uncontrolled-hypertension launch.
Sell if FDA does not approve lorundrostat by the December 22, 2026 PDUFA date or approves it with safety monitoring or population limits that materially prevent broad uncontrolled-hypertension launch.
| 1-3 monthsShort-term scenario | 2026-11-24 | $18.00 | $32.00 | $42.00 | medium evidence confidence | Open window |
| 3-6 monthsMedium-term scenario | 2027-02-24 | $12.00 | $40.00 | $55.00 | medium evidence confidence | Open window |
| 6-12 monthsLong-term scenario | 2027-08-24 | $11.00 | $45.00 | $62.00 | medium evidence confidence | Open window |
These are TickerYou's possible outcomes from the latest saved research. Source strength tells you how solid the supporting information is. It is not a chance of success or a recommendation score. These ranges stay visible as research, but we hide the comparison with today’s price until every required check is complete. We check every price range against what happened when its time frame ends—including the ones we got wrong.
AstraZeneca announced U.S. approval of Baxfendy as a first-in-class aldosterone synthase inhibitor for adults with hypertension inadequately controlled on other medications, with Phase 3 BaxHTN data showing significant blood-pressure reductions.
Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension (astrazeneca.com)Kept as the original record. These do not replace the current sources above.
Three checks come from TickerYou's research review. The app calculates the other three from dated prices, events, and sources. Each check keeps its published weight on every idea; the app never changes a weight to make an idea look better.
How strongly the research engine believes the thesis is right, judged 1-10. This pass judged it 8 out of 10.
Whether the price being paid helps or hurts, judged 1-10: 10 means you are paid to take the risk, 1 means the thesis must be right and the multiple must expand. This pass judged it 6 out of 10.
How contained the damage is if the thesis is wrong, judged 1-10: 10 means a real floor of assets or cash, 1 means a permanent loss. This pass judged it 4 out of 10.
The clearest catalyst still ahead opens in 47 days, on a single dated day.
Price is +17.8% over the last 63 trading sessions — moving with the thesis for this long view.
3 dated claim receipts average 10 out of 10 from explicit source tiers 1, 1, 1; roles: 2 support, 1 challenge, 0 context. Roles establish claim linkage; only the stored tiers set reliability.
This confidence score of 73 out of 100 is the weighted average of the 6 ready checks above, on their 0-10 scales, adjusted to 100.
24 of 100 = chance 0.55 × effect 0.6 × date nearness 0.74.
Previously we believed MLYS should rerate if the accepted lorundrostat NDA converted to approval with a usable hypertension label and launch preparations stayed funded. Live searches found no material cutoff-eligible post-review CRL, delay, label change or safety update. Reopened primary sources still show the December 22, 2026 PDUFA, launch preparations on track, cash runway into 2028, and the competitive challenge from AstraZeneca's already approved BAXFENDY. The thesis is intact but still unresolved and binary.
Previously we believed MLYS should rerate if lorundrostat progressed from accepted NDA to approval with a usable hypertension label and funded launch preparation. Current searches found no cutoff-eligible post-review approval delay, CRL, safety-label event or competitive development that changed the thesis; the reopened August 11 company update remains the usable primary baseline. This confirmed, but did not strengthen, the view; the December PDUFA remains unresolved.
Previously we owned MLYS for a 1-year lorundrostat regulatory-to-commercial rerating. This run found no cutoff-eligible post-review approval, CRL, delay or label change; the August 11 company release still says FDA review continues with a December 22, 2026 PDUFA, launch preparations are on track and cash/investments were $661.4 million, while AstraZeneca's approved Baxfendy and ICER's active aldosterone synthase inhibitor review keep competitive and access risk alive. Thesis intact, but still very event-dependent.
We previously believed MLYS could rerate over one year if lorundrostat moved from accepted NDA to approval with a usable hypertension label and the company had enough cash to reach launch. A live search found no eligible post-review dated FDA rejection, CRL, PDUFA delay, or label limitation before the cutoff; the reopened August 11, 2026 company release still says FDA review continues with a December 22, 2026 PDUFA date, commercial preparations are on track, and cash, equivalents and investments were $661.4 million with runway into 2028. The thesis is confirmed but not strengthened; the unresolved issue is the FDA label and commercial access against AstraZeneca competition.
Opened by the biotech hunt.
TickerYou has not saved a quarterly report for this company yet. We show nothing instead of guessing.
Computed from SEC filings — never model output. Each quarter is named by the fiscal quarter the company itself reported and the month that quarter ended, through the same resolver the Earnings card beside this one uses; where no release established a fiscal label, the quarter is named by its end alone rather than by a quarter number guessed from the date. EPS is GAAP diluted, as filed, so it can legitimately differ from the adjusted figure in the Earnings card (consensus is quoted adjusted). Y/Y compares the same fiscal quarter a year earlier; a comparison that cannot be made honestly is an em-dash that says why.
Jun 2026: the filing establishes the quarter, but comparable year-ago growth and margin are not established.
Comparing the same fiscal quarter a year earlier controls for seasonality. Revenue direction and margin direction together show whether sales are translating into profit, but one quarter is evidence—not a complete thesis.
Watch for the next filing that supplies a same-quarter comparison rather than substituting an older period.
| (USD) | Jun 2026 | vs last year |
|---|---|---|
| Revenue | — | — |
| Profit after costs | $-241.07 M | — |
| Profit per share | -2.85 | — |
| Profit margin | — | — |
† derived: the fiscal year minus its three reported quarters — no 10-K reports a Q4 figure directly. For EPS this assumes per-share figures add across the year.
| Quarter | Revenue | Y/Y | Net income | Margin |
|---|---|---|---|---|
| Mar 2026 | — | — | $-39.34 M | — |
| Dec 2025 | — | — | $-32.23 M † | — |
| Sep 2025 |
| — |
| — |
| $-36.93 M |
| — |
| Jun 2025 | — | — | $-43.27 M | — |
| Mar 2025 | — | — | $-42.21 M | — |
| Dec 2024 | — | — | $-48.95 M † | — |
| Sep 2024 | — | — | $-56.34 M | — |
| Jun 2024 | — | — | $-41.01 M | — |
1M
3M
6M
1Y